Deficiency of hypoxia inducible factor-1α promoted progression of diabetic nephropathy with hypertension

YUEJIANG JIAO1, HONGWEI JIANG2, HAIBO LU2, YIPING YANG1, YANFANG ZHANG1, KUN ZHANG2 and HUI LIU1

1Department of Endocrinology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan 471009;  2Department of Endocrinology, The 1st Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 471033, P.R. China

Received October 9, 2017; Accepted July 13, 2018

DOI: 10.3892/etm.2018.6621

Abstract. The present study was designed to investigate the effect of hypoxia inducible factor-1α (HIF-1α) on diabetic nephropathy (DN) with hypertension. HIF-1α deficient mice (Mx/HIF-1α−/−) were constructed and treated with streptozotocin (STZ) injection for hypertensive DN induction. Normal C57BL/6 mice received STZ or no treatment (normal) were considered as controls. Three days post STZ administration: body weight, fasting blood glucose (FBG), 24 h urinary albumin and systolic blood pressure (SBP) were measured weekly. Periodic acid-Schiff’s staining was performed for histologic analysis of glomeruli damage. In comparison with the normal control, significant upregulation and downregulation of HIF-1α was, respectively, detected in diabetic and HIF-1α+/− mice (P < 0.01). In comparison with STZ-induced diabetic mice, HIF-1α+/− + STZ mice displayed reduced body weight, and increased FBG, urinary albumin and SBP. PAS showed HIF-1α+/− + STZ mice had damaged kidney tissues, with more renal fibrosis and apparent glomerular hypertrophy. These results demonstrated that HIF-1α deficiency accelerated DN progression with increasing hypertension in mice.

Introduction

Diabetic nephropathy (DN) is a leading cause of chronic kidney disease (CKD) and a major complication of diabetes. Hypertension, proteinuria and edema are frequent clinical features of DN patients and experimental DN rats (1). Hypertension elevates blood pressure, increases the kidney damages, and thus becomes an important reason leading to diabetes, DN and end-stage renal failure (ESRF) (1,2). In addition, the morbidity of hypertension in diabetic patients was 1.5 ~ 3.0 times higher than that in non-diabetic populations, showing mutual promotion effect between hypertension and DN.

Diabetic rats always displayed increased oxygen consumption and tissue hypoxia throughout the kidney (3). Chronic hypoxia causes several public health problems including renal fibrosis, reduced renal function, DN, hypertensive nephropathy, CKD, and is the final pathway to ESRF (4-8). Chronic hypoxia-induced hypertension is associated with microvascular and tubulointerstitial injury (9,10). Chronic hypoxia also plays a central pathogenic role in the process of end-stage renal disease (ESRD), including ESRF (11).

The activation of hypoxia-inducible factors (HIFs), however, could prevent the progression of DN (3). Hypoxia inducible factor-1α (HIF-1α) is an oxygen-sensitive gene and is a transcription factor that regulates a wide variety of genes (7). HIF-1α is recognized to be the essential response regulator to hypoxia, and its expression has been evidenced to be correlated with early progression of some diseases including diabetic retinopathy which was caused by hypoxia-induced hyperglycemia (6). Some evidences show HIF-1α’s activation was associated with hypertension of artery, pulmonary or elsewhere (12-14). Researchers had shown that overexpression of HIF-1α in tubular epithelial cells contributed to renal fibrosis progression, and inhibition of HIF-1α expression prevented the progression of renal fibrosis and attenuated DN progression (5,7,11,15). They found HIF-1α-mediated abnormal pathways or genetic dysregulations triggered hypertension (16). For instance, Luo et al showed the elevated expression of endothelial HIF-1α in V-Cadherine/HIF-1α floxed mice promoted the progression of angiotensin II infusion-induced hypertensive CKD (5). On the contrary, the deletion of HIF-1α was reported to attenuated chronic hypoxia induced hypertension, proteinuria, kidney damage and so on (12-14,17). Some studies showed stabilization or activation of HIF-1α was essential under hypoxic conditions (7,18), suggesting the important roles of HIF-1α expression in hypertension. However, little is known about the roles of HIF-1α deficiency in hypertensive DN progression.

The present study was designed to investigate the effect of HIF-1α deficiency on DN with hypertension. Mx/HIF-1α−/− mice were constructed and used as animal HIF-1α−/−-deficient
DN model in this study. Biochemical and physiological changes in normal or HIF-1α deficient mice were detected to assess the influence of HIF-1α deficiency on DN progression.

Materials and methods

Animal and rats methods. Mice labeled with Mx-Cre transgenic mice (JAXMICE: 003556, Strain name: B6.Cg-Tg (Mx1-Cre) 1Cgn/J) were mated to HIF-1α gene LoxP mice (JAXMICE: 007561, B6.129-Hif1atm3Rsjo/H, HIF-1α homozygous floxed mice contain the HIF-1α exon 2 flanked by LoxP sites), both were purchased from the Jackson Laboratories (Jackson Laboratory, Ben Harbor, ME, USA). Mice were allowed twice hybridization, and the identified Mx-Cre + and HIF-1α floxed mice (Mx/HIF-1α+/−) in the third generation were used. Mice were intraperitoneally injected with 400 µl/time poly (I:C; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) every 4 days for a total of 3 times for interferon induction (19). DN induction were performed on C57BL/6 mice (12 weeks old, n=15) and Mx/HIF-1α+/− mice (n=15). All mice received intraperitoneal injection of 140 mg/kg (weight body) streptozotocin (STZ; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) every 21 days for a total of 3 times for interferon induction (19). DN induction were performed on C57BL/6 mice (12 weeks old, n=15) and Mx/HIF-1α+/− mice (n=15). All mice received intraperitoneal injection of 140 mg/kg (weight body) streptozotocin (STZ; Sigma-Aldrich; Merck KGaA). Another 15 mice received injection of equal volume normal saline and were used as blank control. Mice were maintained on a normal diet. Diabetic mice was recognized when fasting blood glucose (FBG) ≥16.7 mmol/l at 72 h post STZ injection. Then animal body weight, 24 h urine albumin, blood pressure, serum glucose were measured weekly. Hypertensive model was recognized with elevated systolic blood pressure (SBP) >140 mmHg. All animals were killed by intraperitoneally administering overdose of sodium pentobarbital (180 mg/kg body weight) at 16 weeks (20). These studies were approved by the Institutional Animal Care and Use Committee Affiliated to Zhengzhou University (Zhengzhou, China).

Blood pressure measurement. At the time of diabetic mice model construction, mice SBP was measured once a week using noninvasive BP tail-cuff with PowerLab system (ADInstruments, Mountain View, CA, USA). The body weight, FBG, 24 h urine albumin, and SBP were available in the first 9 weeks. During the experimental protocol, non-diabetic mice had the expected low level of FBG, urinary albumin, and SBP value. In comparison, HIF-1α+/− mice showed 10% lower FBG, 24 h urinary albumin and SBP during the 16 weeks' experimental protocol (Fig. 2). As expected, the body weight of non-diabetic mice was gradually increased during the experiment period and was already significantly higher than mice treated with STZ at the end of first week (P<0.01; Fig. 2A). On the contrary, the body weight of mice with diabetes (STZ and HIF-1α+/−) was declined during the experiment period. The FBG levels of the diabetic mice (STZ and HIF-1α+/− + STZ) were significantly higher than those of control mice (C57BL/6) at the beginning (P<0.001), and were gradually decreased since the third week, indicating the induction of diabetic mice by STZ administration. In comparison with the gradually increased urinary albumin level in HIF-1α+/− + STZ mice, that of the STZ or C57BL/6 mice did not increased during all the experimental protocol (Fig. 2C), revealing the development of DN in HIF-1α+/− + STZ mice. No increment in urinary albumin was observed in STZ-induced diabetic mice compared with non-diabetic C57BL/6 mice (P>0.05), suggesting there was no DN incidence in STZ-induced diabetic mice. At last we found the diabetic

Biochemistry investigation. Twenty-four hour urine were collected from housed mice. Urine albumin was measured using a ELISA kit (Bethyl Laboratories, Inc., Montgomery, TX, USA). FBG in tail vein were detected weekly using a glucometer (OneTouch Ultra; Lifescan, Inc., Milpitas, CA, USA). FBG in tail vein were detected weekly using a glucometer (OneTouch Ultra; Lifescan, Inc., Milpitas, CA, USA). FBG in tail vein were detected weekly using a glucometer (OneTouch Ultra; Lifescan, Inc., Milpitas, CA, USA).

Histologic analysis. Sixteen weeks later, mice were killed and kidney tissues were fixed, imbedded, and 2 μm sections were stained with periodic acid-Schiff’s (PAS) reagent at 37°C for 10 min and hematoxylin at 37°C for 5 min, followed by image analysis using Image Pro Plus (Media Cybernetics, Silver Spring, MD, USA).

Western blot analysis. Kidney tissues were lysed, prepared, and separated using 10% SDS-PAGE. Then proteins were transblotted onto Millipore PVDF membranes (EMD Millipore, Billerica, MA, USA) which were then blocked with milk. Then membranes were subjected to incubation in the specific primary antibody anti-HIF-1α (1:1,500 in dilution; Cell Signaling Technology, Inc., Danvers, MA, USA) at 4°C overnight, and HRP-conjugated secondary antibodies for 1 h. GAPDH (1:2,000; Cell Signaling Technology, Inc.) was used as internal reference gene. Immunoactive protein bands were analyzed using a Bio-Rad Quantity One software (Bio-Rad Laboratories, Inc., Hercules, CA, USA) by a chemiluminescence reaction system.

Statistical analysis. Data were recorded as means ± SD (standard deviation). Analysis was performed using GraphPad Prism v.6.0 (GraphPad Software Inc., La Jolla, CA, USA). Statistical differences among three groups were analyzed using one-way ANOVA followed by Bonferroni's post hoc test. All datasets were considered normally distributed and analyzed using parametric statistics. P<0.05 was considered to indicate a statistically significant difference.

Results

HIF-1α knockout promotes DN pathogenesis. HIF-1α protein were significantly upregulated in diabetic mice in comparison with the control mice (P<0.01; Fig. 1). The significant down-regulation of HIF-1α protein (not complete knockout) in Mx/HIF-1α+− mice was determined using western blot analysis, which confirmed the knockout of HIF-1α in Mx/HIF-1α+− mice (Fig. 1). The little expression of HIF-1α protein in Mx/HIF-1α+− mice might due to the HIF-1α homolog.

Effect of HIF-1α knockout on body weight, urinary albumin, blood glucose and pressure. The body weight, FBG, 24 h urinary albumin, and SBP in 3 groups were investigated. No death was observed in control (C57BL/6) mice, and 5 mice in STZ group died during the 16 weeks. All Mx/HIF-1α−/−/mice died in the first 9 weeks. So the investigation of HIF-1α−/− mice were available in the first 9 weeks.
HIF-1α expression could be induced by hypoxia and was correlated with early progression of some diseases (6). One of the leading causes of DN in diabetes is renal hypoxia (23). Elevated HIF-1α expression in kidney of mice with hypertensive nephropathy and renal fibrosis had been proved to promote the progression of diseases (5,11). On contrast, the deletion of HIF-1α could attenuate disease progression, and showing protective effect on kidney function. In the present study, we confirmed the upregulation of HIF-1α in hypertensive DN kidneys of mice with renal fibrosis. These demonstrated hypoxic conditions in DN progression and the contribution to kidney damage.

Referring to the HIF-1α deficiency effect, reports showed HIF-1α deficiency could attenuate hypertension of artery, pulmonary, proteinuria, and kidney damage (12-14,17). As reported, hypoxia-induced renal tubular epithelial cell death was prevented by HIF-1α-deficiency, and that was a glucose dependent manner (15). Luo et al (5), demonstrated that HIF-1α deficiency attenuated glomerular damage and renal fibrosis in angiotensin II-infused mice. Shimoda et al (17), showed an partial HIF-1α deficiency of Hif1α (+/-) could blunt hypoxia-induced right ventricular hypertrophy and polycythemia in vivo in PASMCs. Also, in comparison with reduced K+ current density in PASMCs from HIF-1α (+/+), no reduction in K+ current density was observed in PASMCs of hypoxic HIF-1α (+/-) mice (17). Hu et al (13), showed overexpression of HIF-1α in fructose-induced salt-dependent hypertensive rats attenuated high salt + fructose-induced high blood pressure. Taken together, these results showed HIF-1α deficiency benefited to attenuate hypertension or kidney damage.

In the present study, however, we demonstrated that HIF-1α deficiency accelerated hypertensive DN progression in Mx/HIF-1α-/mice. HIF-1α deficient mice showed aggravated kidney damage, higher FBG and SBP levels, and elevated collagen deposition, suggesting the progressive roles of HIF-1α deficiency in STZ-induced DN. Our results was in accordance with the that from Bohuslavova et al (24), who stated the heterozygosity HIF-1α knockout (HIF-1α+/-) mice displayed diabetic cardiomyopathy with decreased LVFS and myocardial function. They found STZ inhibited HIF-1α expression in wild type mice and upregulated HIF-1α and Coll I in HIF-1α-/-mice, suggesting the genetic variation at the HIF-1α locus influenced the extracellular matrix reorganization and risk for fibrosis and diabetic cardiomyopathy. We guessed the aggravated DN in HIF-1α-deficient mice might due to the HIF-1α deficiency-induced deletion of compensatory effect to hypoxia responses, that led to the loss of hypoxia preconditioning. Finally, elevated hypoxic responses in kidney tissues promoted the transdifferentiation of renal tubular epithelial cells to fibroblasts, and facilitated renal fibrosis and irreversible kidney damage.

In the present study, we also found that the urinary albumin in HIF-1α deletion mice were significantly upregulated compared with those in WT mice administrated with STZ. This revealed that HIF-1α deficiency promoted damage on glomerular filtration membrane, thus promoting the filtration of urinary albumin to blood. However, no increment in urinary albumin was found in STZ-treated WT mice compared with control. Generally, the decreased body weight and increased FBG, urinary albumin and SBP were predictors of DM (25). The elevated urinary albumin is a hallmark of diabetic-related kidney disease (26). We did not found the upregulated urinary
albumin in mice in WT group after being administrated with STZ as HIF-1α deficient mice showed, but found the slight histopathologic changes in kidney was in consistence with the unchanged urinary albumin level. This fact might suggested that STZ not definitively induced albumin increment, and also proved that HIF-1α deficiency indeed promoted kidney damage.

Glucose inhibited hypoxia-induced HIF-1α accumulation, and hyperglycemia regulated stability and function of HIF-1α through proteasomal degradation in vivo. Gao et al. (28) showed that hyperglycemia could inhibit HIF-1α expression and attenuate the hypoxic-induced apoptosis of bovine aortic smooth muscle cells (BASMC). So, they suggested that hyperglycemia altered hypoxia-induced changes in vascular cell growth by inhibiting HIF-1α. HIF-1α also mediates the accumulation of collagen by activation of tissue inhibitor of metalloproteinase-1 (TIMP-1) or TGF-β1/Smad3 signaling pathway. Fu et al. (29), showed HIF-1α contributed to regulation of collagen accumulation and renal fibrosis by cross talking with TGF-β1/Smad3 signaling pathway. To further investigate the mechanism related to HIF-1α associated hypertensive DN progression, we would perform more studies to explore underlying mechanisms and signaling pathways.

In summary, we confirmed the HIF-1α upregulation in DN kidney, together with the hyperglycemia and hypertensive. In addition, HIF-1α deficiency did not attenuate DN damage, but inversely accelerated DN progression. We speculated that there must be differential pathways associated with HIF-1α deficiency-promoted DN.

Acknowledgements
Not applicable.

Funding
No funding was received.
Availability of data and materials
The data and materials used in this study are available upon reasonable request from the corresponding author once the paper has been published.

Authors’ contributions
HuL and YJ participated in study design, data analysis and manuscript drafting. HJ, HaL and YY screened patients, collected and analyzed patient data, and revised the manuscript. YZ and KZ were involved in experiment conduction and data analysis.

Ethics approval and consent to participate
The Ethical approval was obtained from the Ethics Committee of The 1st Affiliated Hospital of Henan University of Science and Technology, and all participants signed a consent form prior to enrollment in the study.

Patient consent for publication
Not applicable.

Competing interests
All authors declare they have no competing interests.

References